Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
Dedong Li, Minrun Duan, Xiao Wang, Pengyue Gao, Xin Zhao, Kun Xu, George F. Gao
Abstract
n d e n c e Neutralization of BQ.1, BQ.1.1,and XBB with RBD-Dimer Vaccines To the Editor: Several B.1.1.529(omicron) subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are emerging and have become the dominant strains, such as BF.7, BQ.1, BQ.1.1,and XBB.These variants contain more mutations in the spike protein receptorbinding domain (RBD) than the BA.2 and BA.5 strains (Fig. 1A).Therefore, the potential of these omicron subvariants for immune evasion is a concern.The coronavirus disease 2019 (Covid-19) vaccines with inactivated virus (CoronaVac and BBIBP-CorV) and the ZF2001 protein subunit vaccine 1 have been widely used in China and many other countries.In this study, we obtained serum samples from vaccinees (age range, 18 to 59 years) who had received three homologous doses of ZF2001 (the ZF2001 group, 16 participants) or inactivated vaccine (the inactivatedvaccine group, 16 participants) or two doses of inactivated vaccine plus a booster dose of ZF2001 (the heterologous-boost group, 16 participants) (Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org).this week's letters Neutralization of BQ.1, BQ.1.1,and XBB with RBD-Dimer Vaccines Once-Weekly Semaglutide in Adolescents with Obesity Efficacy and Safety of Bepirovirsen in Hepatitis B New Approaches to Chronic Hepatitis B Focused Cardiac Ultrasonography for Right Ventricular Size and Systolic Function Bivalent Covid-19 Vaccines Figure 1 (facing page).Vaccine-Elicited Neutralizing Antibodies against SARS-CoV-2 Variants in Human and Murine Serum Samples.